{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:05:57Z","timestamp":1784027157324,"version":"3.55.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032626","name":"Unitaid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI146095"],"award-info":[{"award-number":["R01AI146095"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR\/RR-TB) treatment. The implications of these modifications on treatment success are uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600\u2005mg daily within 6 months of initiating an individualized MDR\/RR-TB regimen. We examined 3 linezolid management strategies: immediate change (ie, dose reduction, temporary interruption, discontinuation) within Weeks 1\u20137 after peripheral neuropathy onset, deferred change within Weeks 8\u201326, and no change (ie, continuing linezolid 600\u2005mg daily) during Weeks 1\u201326. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data and applying inverse probability of censoring weights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4\u201318) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.1% (95% CI: 70.5%, 93.0%) for immediate change, 78.6% (95% CI: 66.0%, 86.9%) for deferred change, and 85.2% (95% CI: 80.6%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.84, 1.10) for immediate change and 0.92 (95% CI: 0.77, 1.01) for deferred change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR\/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag361","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:08:48Z","timestamp":1781262528000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of 3 Linezolid Management Strategies for Peripheral Neuropathy in Multidrug- or Rifampicin-Resistant Tuberculosis Treatment: A Target Trial Emulation"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3038-0644","authenticated-orcid":false,"given":"Matthew","family":"Romo","sequence":"first","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8415-133X","authenticated-orcid":false,"given":"Allison","family":"LaHood","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole D","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Partners In Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L","family":"Rich","sequence":"additional","affiliation":[{"name":"Partners In Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9814-0563","authenticated-orcid":false,"given":"Letizia","family":"Trevisi","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-0041","authenticated-orcid":false,"given":"Alena","family":"Skrahina","sequence":"additional","affiliation":[{"name":"National TB Control Program , Minsk ,","place":["Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Oyewusi","sequence":"additional","affiliation":[{"name":"Partners In Health , Maseru ,","place":["Lesotho"]},{"name":"Ministry of Health , Maseru ,","place":["Lesotho"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Bastard","sequence":"additional","affiliation":[{"name":"Department of Field Epidemiology, Epicentre , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-8355","authenticated-orcid":false,"given":"Palwasha Y","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, London School of Hygiene & Tropical Medicine , London ,","place":["United Kingdom"]},{"name":"Interactive Research & Development Global ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-9063","authenticated-orcid":false,"given":"Helena","family":"Huerga","sequence":"additional","affiliation":[{"name":"Department of Field Epidemiology, Epicentre , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3602-5950","authenticated-orcid":false,"given":"Uzma","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive Research & Development Global ,","place":["Singapore"]},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University , Montreal, QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8869-4403","authenticated-orcid":false,"given":"Edwin","family":"Herrera-Flores","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Arzobispo Loayza National Hospital , Lima ,","place":["Peru"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-3096","authenticated-orcid":false,"given":"Hakob","family":"Atshemyan","sequence":"additional","affiliation":[{"name":"National Center for Infectious Diseases , Abovyan ,","place":["Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-1479","authenticated-orcid":false,"given":"Catherine","family":"Hewison","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhmujan","family":"Rashitov","sequence":"additional","affiliation":[{"name":"Partners In Health , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazgul","family":"Samieva","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Bishkek ,","place":["Kyrgyzstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"G\u00f3mez-Restrepo","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Yangon ,","place":["Myanmar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6417-2738","authenticated-orcid":false,"given":"Aga","family":"Krisnanda","sequence":"additional","affiliation":[{"name":"Interactive Research & Development , Jakarta ,","place":["Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinatin","family":"Kotrikadze","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Siraj","sequence":"additional","affiliation":[{"name":"National TB Control Program, Ministry of National Health Services, Regulations & Coordination, Ministry of Health of Pakistan , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Wali","family":"Khan","sequence":"additional","affiliation":[{"name":"National TB Control Program, Ministry of National Health Services, Regulations & Coordination, Ministry of Health of Pakistan , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Ndjeka","sequence":"additional","affiliation":[{"name":"National Department of Health , Pretoria ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Adenov","sequence":"additional","affiliation":[{"name":"National TB Program, Kazakhstan Ministry of Health , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwonjune J","family":"Seung","sequence":"additional","affiliation":[{"name":"Partners In Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1245-7676","authenticated-orcid":false,"given":"Andargachew","family":"Kumsa","sequence":"additional","affiliation":[{"name":"Partners In Health , Addis Ababa ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-5728","authenticated-orcid":false,"given":"Molly F","family":"Franke","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026071406362248300_ciag361-B1","volume-title":"Global tuberculosis report 2025","year":"2025"},{"key":"2026071406362248300_ciag361-B2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0732-8893(01)00334-0","article-title":"A multicenter evaluation of linezolid antimicrobial activity in North America","volume":"43","author":"Ballow","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026071406362248300_ciag361-B3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jinf.2005.04.007","article-title":"Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)\u2014a report of ten cases","volume":"52","author":"von der Lippe","year":"2006","journal-title":"J Infect"},{"key":"2026071406362248300_ciag361-B4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dki148","article-title":"Linezolid for the treatment of multidrug-resistant tuberculosis","volume":"56","author":"Fort\u00fan","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2026071406362248300_ciag361-B5","volume-title":"Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB)","year":"2018"},{"key":"2026071406362248300_ciag361-B6","volume-title":"WHO Consolidated guidelines on tuberculosis. Module 4: treatment and care","year":"2025"},{"key":"2026071406362248300_ciag361-B7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/501356","article-title":"Linezolid-induced inhibition of mitochondrial protein synthesis","volume":"42","author":"De Vriese","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026071406362248300_ciag361-B8","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"2026071406362248300_ciag361-B9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jama.2025.19400","article-title":"Peripheral neuropathy: a review","volume":"335","author":"Mauermann","year":"2026","journal-title":"JAMA"},{"key":"2026071406362248300_ciag361-B10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026071406362248300_ciag361-B11","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2026071406362248300_ciag361-B12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5588\/ijtld.25.0125","article-title":"Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB","volume":"29","author":"Kodama","year":"2025","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026071406362248300_ciag361-B13","doi-asserted-by":"crossref","first-page":"2500315","DOI":"10.1183\/13993003.00315-2025","article-title":"Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis","volume":"66","author":"Kwak","year":"2025","journal-title":"Eur Respir J"},{"key":"2026071406362248300_ciag361-B14","doi-asserted-by":"crossref","first-page":"107302","DOI":"10.1016\/j.ijantimicag.2024.107302","article-title":"Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis","volume":"64","author":"Kuhlin","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2026071406362248300_ciag361-B15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071406362248300_ciag361-B16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026071406362248300_ciag361-B17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026071406362248300_ciag361-B18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/10600280241296841","article-title":"The management of linezolid-induced adverse events in shorter and longer treatment of rifampicin-resistant tuberculosis","volume":"59","author":"Atshemyan","year":"2025","journal-title":"Ann Pharmacother"},{"key":"2026071406362248300_ciag361-B19","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2026071406362248300_ciag361-B20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"2026071406362248300_ciag361-B21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cid\/ciae305","article-title":"Safety and effectiveness of 3 novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan","volume":"79","author":"Rashitov","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026071406362248300_ciag361-B22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1473-3099(24)00228-7","article-title":"Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study","volume":"24","author":"Korotych","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026071406362248300_ciag361-B23","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, delamanid, linezolid and clofazimine for treatment of pre-extensively drug-resistant tuberculosis","volume":"76","author":"Padmapriyadarsini","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026071406362248300_ciag361-B24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijid.2019.04.028","article-title":"Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen","volume":"85","author":"Olayanju","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2026071406362248300_ciag361-B25","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.ijtb.2023.04.006","article-title":"Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: a retrospective multicenter study","volume":"71","author":"Mishra","year":"2024","journal-title":"Indian J Tuberc"},{"key":"2026071406362248300_ciag361-B26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/EDE.0000000000001808","article-title":"A structural description of biases that generate immortal time","volume":"36","author":"Hern\u00e1n","year":"2025","journal-title":"Epidemiology"},{"key":"2026071406362248300_ciag361-B27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026071406362248300_ciag361-B28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026071406362248300_ciag361-B29","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1164\/rccm.202211-2125OC","article-title":"Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis","volume":"207","author":"Trevisi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026071406362248300_ciag361-B30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5588\/ijtldopen.24.0515","article-title":"Effectiveness of a bedaquiline, linezolid, clofazimine \"core\" for multidrug-resistant TB","volume":"2","author":"Zeng","year":"2025","journal-title":"IJTLD Open"},{"key":"2026071406362248300_ciag361-B31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12879-019-4378-4","article-title":"The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens","volume":"19","author":"Khan","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026071406362248300_ciag361-B32","author":"endTB Consortium"},{"key":"2026071406362248300_ciag361-B33","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/01.wnl.0000187119.33075.41","article-title":"Evaluation of a clinical screening tool for HIV-associated sensory neuropathies","volume":"65","author":"Cherry","year":"2005","journal-title":"Neurology"},{"key":"2026071406362248300_ciag361-B34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"Kurbatova","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026071406362248300_ciag361-B35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5588\/ijtld.22.0324","article-title":"Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB","volume":"27","author":"Zeng","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026071406362248300_ciag361-B36","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/cid\/ciae388","article-title":"Effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in treatment of drug-resistant pulmonary tuberculosis: open-label, randomized clinical trial","volume":"79","author":"Padmapriyadarsini","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026071406362248300_ciag361-B37","doi-asserted-by":"crossref","first-page":"106509","DOI":"10.1016\/j.jinf.2025.106509","article-title":"Long term outcomes in drug resistant tuberculosis with bedaquiline, pretomanid and varying doses of linezolid","volume":"91","author":"Daniel","year":"2025","journal-title":"J Infect"},{"key":"2026071406362248300_ciag361-B38","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","article-title":"9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"2026071406362248300_ciag361-B39","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1093\/cid\/ciaf351","article-title":"A short, all-oral regimen for pre-extensively drug-resistant tuberculosis: a multicenter open-label single-arm study","volume":"81","author":"Li","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026071406362248300_ciag361-B40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5588\/ijtldopen.24.0369","article-title":"Experience of piloting BPaLM\/BPaL for DR-TB care at selected sites in Pakistan","volume":"1","author":"Khan","year":"2024","journal-title":"IJTLD Open"},{"key":"2026071406362248300_ciag361-B41","doi-asserted-by":"crossref","first-page":"108473","DOI":"10.1016\/j.ijid.2026.108473","article-title":"Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: a retrospective analysis","volume":"165","author":"Ndjeka","year":"2026","journal-title":"Int J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag361\/68517798\/ciag361.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag361\/68517798\/ciag361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:36:31Z","timestamp":1784025391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciag361\/8706981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag361","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"ciag361"}}